pCPA

pan-Canadian Pharmaceutical Alliance (pCPA): December 2018 Negotiation Status Update   The pan-Canadian Pharmaceutical Alliance Office (pCPAO) issued the status of brand negotiations as of December 31, 2018. The key highlights since the November update are: 5 products received a final HTA recommendation, for a total of 13 files under consideration 2 products initiated pCPA negotiations, for a total of 46 active negotiations 7 negotiations were completed for a total of…

pan-Canadian Pharmaceutical Alliance (pCPA): November 2018 Negotiation Status Update   The pan-Canadian Pharmaceutical Alliance Office (pCPAO) has issued the status of brand negotiations as of November 30, 2018. The key highlights since the October update are: 7 new drug products have initiated pCPA negotiations, for a total of 51 active negotiations; 9 negotiations were completed for a total of 225 completed negotiations; and 2 negotiations were closed since the last…

On November 27, 2018 the BC Ministry of Health changed coverage of glatiramer products, GLATECT™ and COPAXONE®, which demonstrates a shift from previous public drug plan approaches for funding of subsequent entry products (biosimilars) for chronic diseases.   Background   GLATECT™ is the first subsequent entry glatiramer-based treatment available for reimbursement for RRMS in Canada – i.e. a follow on product to Copaxone®. It is classifed as a non-biological complex…

pan-Canadian Pharmaceutical Alliance (pCPA): October 2018 Negotiation Status Update   The pan-Canadian Pharmaceutical Alliance Office (pCPAO) has issued the status of brand negotiations as of October 31, 2018. The key highlights since the September update are: 6 new drug products have initiated pCPA negotiations, for a total of 57 active negotiations; 2 negotiations were completed for a total of 216 completed negotiations; and 1 negotiation was closed since the last…

Summary of Expensive Drugs for Rare Diseases (EDRD) Working Group Webinar   Signals Decoded:   Stakeholder consultation is underway on a supplemental process for complex/specialized drugs that builds upon the existing national HTA and reimbursement process to make responsive funding decisions with a focus on non-oncology therapies. The supplemental process is a significant development in EDRD policy and it looks to streamline the evaluation and reimbursement process of eligible drugs…

Panel 6: Presidents’ Roundtable   Panel Description: This session brought together general managers from three innovative pharmaceutical companies operating in Canada to explore their insights on how the current reimbursement environment is impacting their company, its decision-making and patient access. Moderator: Barbara Jaszewski Panelists: Peter Brenders, Brian Canestraro and Ben Faienza Barbara Jaszewski: CAHR 201 has been a great way to get a fast introduction to all the changes that…

Panel 5: Patient Support Programs   Panel Description: This session will help participants develop a better understanding of why PSPs are well-suited to support the development of outcomes-based agreements. It will suggest effective ways that PSPs can be developed to support data collection for HTA. Finally, current pCPA perspectives on PSPs and the opportunity for data collection within programs will be explored by this panel. Moderator: Allison Wills Panellists: Sang…

Panel 4: Pan-Canadian Pharmaceutical Alliance   Panel Description: This panel will focus on recent events surrounding the pCPA and how public payers believe that PMPRB reform may impact upcoming pCPA negotiations. Moderator: Sherry O’Quinn Panelists: Imran Ali, Jessica Arias and Heather McDonald Sherry O’Quinn: Our focus is on recent events around the pCPA and the pharmaceutical landscape. A lot of this discussion is framed around healthcare sustainability. Here to take…

Aligned Reviews Between Health Canada (HC) and Health Technology Assessment Organizations (HTAs)   Date: September 26th, 2018 Time: 10:00 AM - 11:30 AM Presenters: Alex Chambers (CADTH), Virginie Landreville (INESSS), M Coyer (HC), and T Richter (CADTH) Purpose: To describe the HC-HTA (CADTH and INESSS) aligned review process in more detail, and discuss any questions regarding this initiative. This initiative aims to improve regulatory review in order to obtain more…

pan-Canadian Pharmaceutical Alliance (pCPA): September 2018 Negotiation Status Update   The pan-Canadian Pharmaceutical Alliance Office (pCPAO) has issued the status of brand negotiations as of September 30, 2018. This month, MORSE Consulting Inc. provides our standard update along with two charts demonstrating the trends for the average time under consideration and average duration of negotiation for completed and closed files from August 2017 to September 2018. Of note: Average Time…

pCPA Biosimilars/Biologics Policy Directions Webinar   On Tuesday September 25, 2018 the pan-Canadian Pharmaceutical Alliance Office (pCPAO) hosted a one-hour webinar for industry to introduce the Biologics Policy Directions and pCPA Negotiations document. The objectives of the webinar were to: Present the pCPA Biologics Policy Directions & pCPA Negotiations document; and Invite and address industry feedback. This edition of MORSE Signals provides an overview of the webinar and provides key…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The August 31, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are: 7 negotiations were completed, while none were closed for a total of 235 completed/closed negotiations; 9 new drug products have initiated pCPA negotiations, for a total of 48 active negotiations; No new drug products were added to the “No pCPA Negotiations”…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The July 31, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are: 9 negotiations were completed, while none were closed for a total of 228 completed/closed negotiations; 8 new drug products have initiated pCPA negotiations, for a total of 46 active negotiations; No new drug products were added to the “No pCPA Negotiations”…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The June 30, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are: Three negotiations were completed, while one negotiation was closed for a total of 193 completed negotiations and 26 closed negotiations; Eight new drug products have initiated pCPA negotiations, for a total of 47 active negotiations; No new drug products were added…